New Discovery Boosts mRNA Drug Potency and Protein Production
Scientists at Johns Hopkins Medicine have identified a biological modification that allows messenger RNA therapies to produce more therapeutic proteins inside human and animal cells, according to findings published in the journal Nature. The discovery centers on an RNA modification known as N4-acetylcytidine, or ac4C, which researchers suggest could eventually lead to treatments for cancer, infectious diseases, and autoimmune disorders at lower doses.
- Researchers at Johns Hopkins Medicine published findings in Nature showing that an RNA modification called ac4C increases therapeutic protein production in cells compared to standard industry platforms.
- Laboratory tests on human dendritic cells and mouse liver cells demonstrated that ribosomes move nearly twice as fast along ac4C-modified mRNA than along standard m1Ψ-modified mRNA.
- The increased translational speed helps prevent molecular bottlenecks, suggesting future mRNA therapeutics could achieve goals with lower overall dosages.
Understanding the Molecular Bottleneck in mRNA Therapeutics
Current mRNA applications—including the vaccines used against Covid-19—rely on a modification called N1-methylpseudouridine, or m1Ψ. According to research led by Bin Wu, associate professor of biophysics and biophysical chemistry at the Johns Hopkins University School of Medicine, the standard m1Ψ platform can cause ribosomal bottlenecks.
Inside the cells, ribosomes move along mRNA strands to read genetic instructions and assemble proteins. When ribosomes bunch up, translation efficiency is affected. To evaluate whether alternative modifications might clear these traffic jams, the Johns Hopkins team examined ac4C, one of more than 170 RNA modifications identified in nature but only a small part of which have been studied for developing mRNA therapies.
Translational Speed and Dosage Implications
Using imaging techniques on human dendritic cells cultivated in the laboratory alongside mouse liver cells, the investigators tracked ribosomal movement. The data revealed that ribosomes transit across ac4C-modified mRNA strands at nearly twice the velocity observed on standard m1Ψ-modified strands. By avoiding the molecular congestion observed with standard industry platforms, cells directed by ac4C produced more target proteins.
This efficiency gain carries implications for dosing. Because the utility of mRNA platforms relies on instructing cells to produce temporarily a given protein, enhancing output per transcript could reduce the doses required for a clinical effect.
Next Steps in Preclinical Evaluation
Despite the yield improvements observed in cell and animal models, ac4C remains at the experimental stage. Researchers emphasize that verifying safety in living organisms is necessary before this discovery can become a key element in the development of the next generation of mRNA drugs.
*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*